Last $168.21 USD
Change Today -1.76 / -1.04%
Volume 1.9M
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 6:40 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$170.67
Previous Close
$169.97
Day High
$171.27
Day Low
$167.26
52 Week High
06/30/14 - $174.49
52 Week Low
11/7/13 - $88.34
Market Cap
51.7B
Average Volume 10 Days
1.2M
EPS TTM
$4.76
Shares Outstanding
307.6M
EX-Date
08/13/14
P/E TM
35.3x
Dividend
$0.20
Dividend Yield
0.12%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,700 Employees
Last Reported Date: 08/5/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Non-Executive Officer
Total Annual Compensation: $641.5K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan Inc to Cut 25 Jobs at Main Irish Operation

Allergan Inc. is to make 25 job cuts at its main Irish operation. The company is seeking redundancies at its Westport facility where it has a workforce of 900. The company said the lay-offs were part of plans for a global restructuring announced in July.

Pershing Square, Valeant Pharma Settle Litigation with Allergan

Pershing Square Capital Management, L.P. and Valeant Pharmaceuticals International, Inc. announced an agreement with Allergan, Inc. (AGN) to settle pending litigation before the Delaware Court of Chancery. Allergan has agreed to unconditionally call and hold a special meeting of its shareholders on December 18. Allergan has reserved the right to continue to pursue existing litigation in federal court in California but will no longer seek the invalidation of any special meeting requests. Pershing Square is a SEC registered investment advisor to private investment funds. A fund managed by Pershing Square is Allergan's larger shareholder owning approximately 9.7% of shares outstanding. Pershing Square announced that, at the special meeting, Allergan shareholders will have the opportunity to voice their support for a number of critical matters, including the removal of six incumbent members of the board, the appointment of an independent slate of directors, amendments to bylaws to eliminate restrictions on the calling of a special meeting.

Sources Say Allergan May Buy Jazz Pharmaceuticals

Jazz Pharmaceuticals Public Limited Company (NasdaqGS:JAZZ) is seen as a potential takeover target for Allergan Inc. (NYSE:AGN), Orange County Business Journal reported. Website dealReporter cited three unnamed industry bankers who said Jazz Pharmaceuticals Public Limited Company (NasdaqGS:JAZZ) would be the most likely target if Allergan Inc. (NYSE:AGN) seeks a defensive deal to ward off Valeant Pharmaceuticals International, Inc. (TSX:VRX) and Bill Ackman. Shares of Jazz Pharmaceuticals PLC rose after an industry website said it would likely be the most viable deal target for Allergan Inc. Jazz’s shares closed up 7% to a market value of $10.1 billion. Allergan shares closed up 1% to a market value of $49.6 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $168.21 USD -1.76

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $241.81 USD +3.88
Astellas Pharma Inc ¥1,601 JPY +17.00
Mylan Inc/PA $47.36 USD -1.07
Regeneron Pharmaceuticals Inc $358.92 USD -3.82
Shire PLC 5,290 GBp -30.00
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 38.9x
Price/Sales 7.5x
Price/Book 7.4x
Price/Cash Flow 36.1x
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.